VEGFA and age-related macular degeneration: The mainstay of treatment for neovascular ARMD (nARMD) remains anti-vascular endothelial growth factor (VEGF) intravitreal injections due to the high efficacy and tolerable safety profile demonstrated in clinical trials [2, 3].